Jason Lettmann insider trades

Open-market stock purchases and sales by Jason Lettmann, CHIEF EXECUTIVE OFFICER at ALX Oncology Holdings Inc, from SEC Form 4 filings since Oct 31, 2016.

Track record: 40% of 5 scored buys are up 5% or more since purchase, averaging -37%.

Recent trades

DateStockTradeValue
Mar 19, 2026ALXO ALX Oncology Holdings IncSold$26.7K
Feb 17, 2026ALXO ALX Oncology Holdings IncSold (not open market)$5K
Jan 26, 2026ALXO ALX Oncology Holdings IncBought (not open market)—
Oct 14, 2025ALXO ALX Oncology Holdings IncBought (not open market)—

Companies traded

  • ALXO ALX Oncology Holdings Inc: 5 buys, 31 sales, last Mar 19, 2026
  • RARX Ra Pharmaceuticals, Inc: 3 buys, 1 sale, last Jun 20, 2017

Get free alerts when Jason Lettmann files a new trade →